A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma.

Rodrigo Ramella MunhozGuilherme Nader-MartaVeridiana Pires de CamargoMarcello M QueirozJade Cury-MartinsHermínia RicciMarcela R de MattosThiago A F de MenezesGuilherme U C MachadoEduardo BertolliMilton BarrosCarina E de SouzaFábio FrankeFabio O FerreiraOlavo FeherGilberto de Castro

Published in: Cancer (2022)

Nivolumab resulted in robust antitumor activity, sustained responses, and good tolerability in systemic treatment-naive patients with aCSCC. These data provide further evidence to support the use of ICI as the standard treatment of aCSCC.

Keyphrases

squamous cell carcinoma
locally advanced
open label
small cell lung cancer
radiation therapy
clinical trial
neoadjuvant chemotherapy
hiv infected
rectal cancer
big data
lymph node
phase ii study
replacement therapy
smoking cessation